---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000051"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-07-29T10:33:23+00:00"
generated_at: "2026-07-29T10:35:05.755622+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q2 net sales $5.44B (+7.5% reported); adjusted EPS $0.86 beats guidance

## Summary
- Net sales $5.442B, up 7.5% reported (guidance 5.5-7.5%); adjusted EPS $0.86 (guidance $0.82-$0.84).
- GAAP EPS $0.61 vs $0.53 YoY; net income $907M.
- Cardiovascular segment grew 8.3% reported; MedSurg 5.9%.
- Completed $2B accelerated share repurchase (~40M shares); invested $1.5B in MiRus for 34% stake and TAVR option.
- Clinical data: FRACTURE IVL trial met endpoints; FARAPULSE PFA showed superiority over drugs in AVANT GUARD.

## SEC filing metadata
- accession: 0000885725-26-000051
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-07-29T10:33:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/0000885725-26-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/bsx-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000051
- JSON: https://secwatch.observer/filing/0000885725-26-000051.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.